Formycon Secures EU Approval for Biosimilar FYB203

Formycon AG has received EU approval for its biosimilar FYB203 (aflibercept), branded as AHZANTIVE® and Baiama®. Approved by the European Commission, FYB203 is intended for treating neovascular age-related macular degeneration and several other retinal conditions. This biosimilar expands treatment options for patients previously treated with Eylea®, a product with significant global sales.

Formycon plans to market FYB203 across Europe with Teva Pharmaceuticals handling distribution under AHZANTIVE®. This marks a significant achievement in providing a cost-effective alternative, following FYB203's prior approval by the U.S. FDA. The approval reflects Formycon's commitment to offering high-quality therapies and improving patient access to affordable medicines.